Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fei Su

Showing results (451-460 of 457) with videos related to

Pageof 46
Sort By:
You have reached the last page of results.This site can display upto 457 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> MutationPanagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
Nature Communications|March 28, 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerLuigi Formisano, Yao Lu, Alberto Servetto, et al.
Clinical Pharmacology and Therapeutics|November 15, 2023
Methodology for Good Machine Learning with Multi-Omics DataThibaud Coroller, Berkman Sahiner, Anup Amatya, et al.
Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The New England Journal of Medicine|June 1, 2019
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The New England Journal of Medicine|January 20, 2012
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsFei Su, Amaya Viros, Carla Milagre, et al.
Pageof 46

Showing results (451-460 of 457) with videos related to

Sort By:
Pageof 46
You have reached the last page of results.This site can display upto 457 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> MutationPanagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
Nature Communications|March 28, 2019
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerLuigi Formisano, Yao Lu, Alberto Servetto, et al.
Clinical Pharmacology and Therapeutics|November 15, 2023
Methodology for Good Machine Learning with Multi-Omics DataThibaud Coroller, Berkman Sahiner, Anup Amatya, et al.
Nature|September 9, 2010
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, Peter Hirth, James Tsai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The New England Journal of Medicine|June 1, 2019
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
The New England Journal of Medicine|January 20, 2012
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsFei Su, Amaya Viros, Carla Milagre, et al.
Pageof 46